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A B S T R A C T
The literature describing tuberculosis (TB) in hematopoietic stem cell transplant (HSCT) recipients is
scant, even in countries where TB is common. We describe a case of pulmonary TB in a patient who
underwent HSCT and review the English language literature on this subject. An extensive PubMed and
Ovid search was undertaken for the period January 1980 to March 2009; the search terms used were
‘Mycobacterium tuberculosis’ or ‘tuberculosis’, in combination with ‘hematopoietic stem cell transplanta-
tion’ or ‘bone marrow transplantation’. The patient in the present case report underwent allogeneic
transplantation and developed TB 8 days after his HSCT. The patient had received vaccination against TB
in childhood. During the year prior to the HSCT he had had contact with a relative who had pulmonary
TB. On day 3 of anti-TB treatment he developed pericarditis. The patient received anti-TB treatment for 6
months without major problems. From the literature review, we found 34 related studies, 25 on the
clinical manifestations of TB. Most of the reports were from Asia (48%), and the incidence of TB varied
from 0.0014% in the USA to 16% in Pakistan. TB occurred at between +21 and +1410 days post-HSCT
(257.2 days the median), and the lung was the organ most frequently involved. Mortality varied from 0%
to 50% andwas higher in allogeneic HSCT. There is no consensus regarding screening with the tuberculin
skin test or primary prophylaxis for latent TB, and further research into this is necessary in developing
countries with a high prevalence of TB.
 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Hematopoietic stem cell transplant (HSCT) recipients have
severe impairment in cell-mediated immunity as a result of the
conditioning regimen used, immunosuppressive therapy, and graft-
versus-host disease (GVHD).1,2 Accordingly, they are susceptible to
bacterial, viral, and fungal infections.1,2Mycobacterial infections can
also occur in these patients, although the incidence is not high, even
in countrieswhere tuberculosis (TB) is common.2Data from theUSA
show that the incidence of Mycobacterium infection among HSCT
recipients ranges from 0.0014% to 3%.1,3–5 Countries in which the
prevalence of TB in the general population is higher than in the USA
have reported incidencesvarying from1.6% inSpain6 andTurkey,7 to
8.57% in Hong Kong and Taiwan and 16% in Pakistan.8–11* Corresponding author.
E-mail addresses: costasilviaf@ig.com.br, silviacosta@usp.br (S.F. Costa).
1201-9712/$36.00 – see front matter  2009 International Society for Infectious Disea
doi:10.1016/j.ijid.2009.08.001We describe herein a case of pulmonary and probable
pericarditis TB in a patient who underwent HSCT, and review
the English language literature on this subject.
2. Review methodology
2.1. Literature search
An extensive PubMed and Ovid searchwas performed using the
search terms ‘Mycobacterium tuberculosis’ or ‘tuberculosis’, in
combination with ‘hematopoietic stem cell transplantation’ or
‘bone marrow transplantation’, and ‘allogeneic and autologous
transplant’. A speciﬁc search for ‘pericarditis due toMycobacterium
tuberculosis’ and ‘hematopoietic stem cell transplantation’ or ‘bone
marrow transplantation’ was performed.
Studies that focused on stem cell transplantation for other
diseases, such as autoimmune or solid tumor, were excluded.
The search was performed for the period January 1980 to March
2009.ses. Published by Elsevier Ltd. All rights reserved.
Figure 1. Computed tomography (CT) scan of the chest showing budding. A new chest CT at 3 days after the onset of pulmonary symptoms, on day 11 post-HSCT, showed
pericardial and pleural effusion.
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Eligible studies consisted of all those that linked TB with
hematological patients who underwent stem cell transplantation
and that described a case report or incidence/prevalence of TB in
this patient population. There were no requirements for a
minimum number of patients or for study design.
3. Case report
During the year 2007, 235 HSCTwere performed at the Hospital
das Clinicas of the University of Sa˜o Paulo. Only one case of TB was
documented during this period.
A 21-year-old man, born in the northeast of Brazil, who was
diagnosedwith severe aplastic anemia in August 2007, underwent a
siblinghuman leukocyte antigen (HLA) fullmatchedallogeneicHSCT
on September 24, 2007. The patient received busulfan (4 mg/kg) and
cyclophosphamide (200mg/kg) as conditioning treatment, and
prophylaxis with acyclovir, ﬂuconazole, and cefepime. The patient
developed fever on day 3 following the HSCT. The cefepime was
replaced progressively with meropenem, teicoplanin, polymyxin B,
and voriconazole. Despite a normal chest X-ray in his HSCT pre-
screening, hedeveloped fever andpulmonary symptoms (chest pain,
dyspneaandhypoxemiawithoutcough)8daysafterthetransplant.A
chest computed tomography (CT) scan showed an image suspicious
of TB (tree-in-bud), and sputum examination revealed the presence
of acid-fast bacilli (AFB; +++/+4) (Figure 1). The patient had received
vaccinationagainstTBinchildhood.Duringtheyearprior totheHSCT
he had had contact with an aunt who had diagnosed pulmonary TB.
The prescribed antibiotics were interrupted and he was started on
alternative anti-TB treatment (ATT) with isoniazid, ethambutol, and
oﬂoxacin, because he had a total bilirubin level of 3.0 mg/dl. After 3
days of treatment he developed symptoms of pericarditis, and an
electrocardiogram revealed inversion of the T wave. A new chest CT
(Figure 1) and an echocardiogram showed pericardial effusion
without cardiac tamponade. Since the patient had a low platelet
count, the pleural and pericardial ﬂuids could not be examined.
Prednisone 40 mg/day was added to his ATT at this time.
On day +16 post-HSCT, his bilirubin level was normal and the
alternative ATT was replaced with ﬁrst-line medication (rifampin,
isoniazid, pyrazinamide). After 8 days of this ATT, the patient was
afebrile with a signiﬁcant improvement in his symptoms and was
discharged. Despite the positive AFB smear, three mycobacterial
cultures remained negative. The patient received the ATT for 6
months without major problems.
4. Results of the review
Thirty-four articles were identiﬁed in our literature search.
However, only 25 described TB in hematological patients who hadundergone HSCT.1,3–5,7–10,18–33 Four studies concerned TB screen-
ing with the tuberculin skin test (TST) and prophylaxis,12–15 one
involved an animal model,16 and one was on the subject of genetic
susceptibility to Mycobacterium.17 Among the 25 studies on TB
infection in HSCT recipients, 12 (48%) were from Asia,8–
10,19,21,22,24,25,27,31–33 ﬁve from the USA,1,3–5,23 ﬁve from Eur-
ope,6,7,28–30 one from Australia,26 one from the Middle East,18 and
one from Latin America20 (Table 1). The incidence of TB in HSCT
ranged from 0.0014% to 16% (Table 1). The time to diagnosis of TB
varied from +21 to +1410 days (median 257.2 days) after the HSCT.
The lung was the organ most frequently involved (Table 1). There
were only two reports of pericarditis.19,25 Most of the TB cases
were described in relation to allogeneic HSCT, and the mortality in
this type of HSCT was high, ranging from to 0% to 50% (Table 1).
5. Discussion
The present report describes a case of pulmonary TB and
probable pericarditis due to TB that was diagnosed early (8 days)
after the allogeneic HSCT. There are few reports of a diagnosis of TB
during the ﬁrst two weeks post-HSCT (Table 1). Most cases of TB
described in the literature occurredmore than 90 days after HSCT.2
The diagnosis of TB in the present report was made only by the
positive AFB smear result. Unfortunately, three mycobacterial
sputum cultures from our patient remained negative. A positive
AFB smear with negative culture could be considered a laboratory
failure to isolate Mycobacterium.35–37 In reports in the literature,
positive AFB smear with negative cultures occurs in 0.5% to 25.6%
of cases.2,35–37 A recently published review of 56 cases of TB among
HSCT recipients, showed that only 55% of cases were diagnosed
with culture. Histology (20.3%) was the second most common
approach for diagnosis, and AFB smear was responsible for 26% of
diagnoses.2 In this study, molecular techniques were rarely used
for diagnosis (3.7%), and were mainly used in conjunction with
other diagnostic approaches.2 Since the results of mycobacterial
culture take 3–4 weeks, the commencement of TB treatment is
usually based on the AFB smear ormolecular technique results. The
positive epidemiology in our patient, his close contact with a
relative with TB, his thorax CT scan with an image suspicious of TB
(tree-in-bud), his positive AFB smear results, and lastly, his rapid
response to the TB treatment, led us to the diagnosis of pulmonary
TB.
Another interesting ﬁnding in our patient was the development
of pericarditis. There are only two cases of pericarditis due TB
described in this population of patients, both occurring in
allogeneic HSCT.19,25 One patient developed symptoms on day
+19 post-HSCT.19 The other case was a patient with previous TB
who underwent allogeneic HSCT. The patient developed chronic
GVHD and symptoms of pericarditis 30 days after transplant.25
Both patients received ATT for 6monthswith cure.19,25 Despite the
Table 1
Description of 25 studies regarding TB among HSCT published in the literature between January 1980 and March 2009
Authors (Ref.) Country (period
of study)
Patients with
TB/No. of HSCT
Type of HSCT TB incidence Time from HSCT to TB (range) Site of infection (n) Outcome
Navari et al. (1) USA (1983) 2/682 2 HSCT 0.0014% ND Lung No death
Kurzrock et al. (5) USA (1983) 2/90 2 Allogeneic 3% ND Lung ND
Roy and Weisdorf (3)a USA (1974–1984) 11/2241 9 Allogeneic,
2 autologous
0.49% 180 to +100 days post-HSCT Lung (1), central venous
catheter (4), bone marrow
(2), maxillary sinus (1),
vertebral (1), bacteremia
(3), skin (1), pleural
effusion (1)
2 Deaths
Keung et al. (4) USA (1996) Case report Autologous ND +10 days post-HSCT Lung Death
Ip et al. (8) Hong Kong (1991–1994) 10/183 Allogeneic 5.5% +23 to +550 days post-HSCT Lung 3 Deaths from other
complications of BMT
Aljurf et al. (18) Saudi Arabia (1986–1997) 4/641 Allogeneic 0.62% +120 to + 600 days post-HSCT Lung, CNS, spine 2 Deaths before
diagnosis
Budak-Alpdogan
et al. (7)
Turkey (1988–1998) 5/351 Allogeneic 1.42% +300 to +1410 days post-HSCT Lung (80%), renal (20%) Cure
de la Ca´mara
et al. (6)
Spain (2000) 8/5, 147 Autologous;
12/2, 866 allogeneic
HSCT 0.15%;
0.41%
Median +324 days post-HSCT Lung (80%) 25% Deaths
Ku et al. (9) Taiwan (6-year period) 8/350 Allogeneic 2.3% Median 3.8 months
(1–33.5 months) post-HSCT
Lung 4 (50%) Deaths
Ullah et al. (19) Pakistan (2001–2006) 4/154 Allogeneic 2.6% +21 to +241 days post-HSCT Lung (3),
mediastinum (1),
pericardium (1)
1 Death
Altclas et al.b (20) Argentina (1999) Case report Allogeneic - +300 days post-HSCT Lung Improvement;
no relapse
Maeda et al. (21) Japan (2002–2004) 3/113 Allogeneic,
cord blood
2.7% +34 to +61 days post-HSCT Disseminated 2 Deaths
Khan et al. (22) Pakistan (2005) 4/25 Allogeneic 16% Median 21 weeks Lung (52%) ND
Garces Ambrossi
et al. (23)
USA (1993–2001) 4/577 Allogeneic 0.69% +60 to +300 days post-HSCT Lung (3), lymph node (1) 1 Death, 3 cure
Wang et al. (10) Taiwan (1995–2001) 3/35 Allogeneic 8.57% +124 to +605 days post-HSCT Lung 1 Death
George et al. (24) India (1986–2001) 9/304 Allogeneic 2.3% More than 30 days post-HSCT Disseminated (55%),
bone (22%)
Cure
Lee et al. (25) Korea (1996–2003) 9/295 HSCT 3.1% +45 to +165 days post-HSCT Lung (8), pericardium (1) 5 Deaths, 4 cure
Erdstein et al. (26) Australia (3 years) 4/127 Allogeneic 2.3% 3 to 15 months Lung 2 Deaths
Yoo et al. (27) Korea (1998–1999) 242 Allogeneic 3% <100 to 734 days post-HSCT ND Cure
Kerridge et al. (28) England, 2003 Case report Allogeneic - Day +40 Disseminated Cure
Kindler et al. (29) Germany (1999) Case report Allogeneic - Around 30 days post-HSCT Disseminated Death
Campos et al. (30) Portugal (1995) Case report
3/310 (previous)
Allogeneic 0.9% ND Lung and CNS Death
Ullah et al. (31) Pakistan (2002–2007) 2/37 Allogeneic 5.4% ND Lung Cure
Kumar et al. (32) India (2004–2007) 1/40 Allogeneic 2.5% After day 100 Disseminated Death
Shima et al. (33) Japan Case report Allogeneic - 50 days after second HSCT Disseminated Death
TB, tuberculosis; HSCT, hematopoietic stem cell transplantation; ND, not described; BMT, bone marrow transplantation; CNS, central nervous system.
a Mycobacteria isolated: M. tuberculosis (2), M. avium-intracellulare (2), non-tuberculous mycobacteria (M. fortuitum and M. chelonae) (7).
b Case report: M. tuberculosis resistant to rifampin, isoniazid, ethambutol, pyrazinamide, streptomycin, ethionamide and rifabutin.
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TB, his condition improved rapidly with the ATT and steroid use.
The case described in the present study showed a patient with a
tree-in-bud appearance on chest CT scan, an image commonly
described in pulmonary TB. A recently published study retro-
spectively analyzed chest radiographic and CT ﬁndings of 10
patients who had undergone HSCT and developed TB. It was shown
that themost common abnormalitieswere air–space consolidation
(100%) and nodules (80%), and on chest CT scans (n = 7), the most
common parenchymal lesions were consolidation (100%), nodules
(71%), tree-in-bud appearance (43%), and ground-glass opacity
(43%).34
TB in HSCT patients is mainly due to reactivation of latent
infection.2 In countries where TB is endemic, pulmonary TB could
be due to a new infection. In the present report, the patient had a
relative who had TB in the year before his HSCT. Our hospital does
not do screening for TB with TST pre-HSCT. TB screening using TST
in HSCT is controversial.12–15 T cells play an important role in
protective immunity against TB. The question arises as to whether
TST-speciﬁc memory T cells are transferred from the marrow
donor to the recipient and persist in the long-term.12
Isoniazid prophylaxis in HSCT recipients with only radiological
ﬁndings suggestive of past inactive TB infection was not found to
signiﬁcantly alter the incidence of TB infection.24 Tavil et al.
evaluated the frequency of TST positivity among 26 patients and
their donors, to investigate whether tuberculin positivity of a
recipient or donor inﬂuences the rate of TB disease or transplant-
related events; they also evaluated the effectiveness of isoniazid
prophylaxis administered to those with a positive TST.15 The
frequency of TST positivity was 23% (n = 6) among recipients and
also 23% (n = 6) among donors. Two recipients and ﬁve donorswith
a positive TST received isoniazid prophylaxis for 6 months. The
transplantation procedure was not postponed for either recipient
or donor TST positivity. Despite the high frequency of TB in their
country, they did not detect any case of TB at their center, either
among the TST screened (n = 26) or the non-screened (n = 128).15
The Infectious Diseases Working Party of the European Blood
and Marrow Transplant Group conducted a survey to obtain
information about the frequency, presentation, and treatment of
mycobacterial infection in HSCT recipients.11 Among 29 centers,
including one Brazilian hospital, mycobacterial infection was
diagnosed in 0.79% of 1513 allogeneic and 0.23% of 3012
autologous HSCT recipients during 1994–1998, a median of 160
days after transplantation. The mean interval between ﬁrst
symptoms and diagnosis was 29 days. The prevalence of
mycobacterial infection was highest among those who had
received matched unrelated or mismatched HSCT from related
donors. The lung was the organ most frequently involved (55% of
patients), with cough present in 48%, dyspnea in 32%, and
hypoxemia in 29%. Five patients (16%) died, all of whom had
received an allogeneic HSCT. Of the participating centers, 51% had a
program of vaccination against TB in their country, only 10%
systematically screened their patients by TST before transplant,
and 51% screened in the case of clinical suspicion.11
The literature review undertaken in the present study showed
that most of the reports of TB were from Asia (48%), that the
incidence of TB varied from 0.0014% (USA) to 16% (Pakistan), and
that the lung was the organ most frequently involved (Table 1).
Mortality varied from 0% to 50% and was higher among allogeneic
HSCT and patients with disseminated disease (Table 1).
In conclusion, TB is more frequent and has a worse prognosis in
allogeneic HSCT, and generally occurs at between +8 and +1410
days after HSCT. The lung is the organ most often involved and
pericarditis is rare or under-diagnosed. Risk factors associatedwith
TB in allogeneic HSCT are use of steroid and GVHD. There is no
consensus regarding screeningwith TST or primary prophylaxis forlatent TB, and further research into this is needed in developing
countries with a high prevalence of TB.
Conﬂict of interest: No conﬂict of interest to declare.
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